Filing Flows › Companies › Charles River Laboratories International › Timeline
Charles River Laboratories International stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions+97.4% to $337.52
Charles River Laboratories International (CRL) stock rose 97% over the last 252 sessions, to $337.52. On the way it reported 4 quarters, its insiders filed 3 open-market trades and 13 Form 144 notices of planned sales, and the company filed 3 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 4, 2026 | Earnings | Earnings: beat the EPS estimate by 3.5% | −7.5% (−9.2% vs SPY) | — | — |
| Oct 22, 2026 | Form 144 | Form 144: James Foster plans to sell $8.4M | −1.5% (−0.3% vs SPY) | +8.1% (+8.2% vs SPY) | — |
| Oct 21, 2026 | Form 144 | Form 144: Shannon M. Parisotto plans to sell $743K | +8.9% (+8.4% vs SPY) | +12.9% (+12.8% vs SPY) | — |
| Oct 5, 2026 | Form 144 | Form 144: Shannon M. Parisotto plans to sell $309K | +6.9% (+6.2% vs SPY) | +3.9% (+2.8% vs SPY) | +15.4% (+17.7% vs SPY) |
| Aug 25, 2026 | Form 144 | Form 144: James Foster plans to sell $10.1M | −0.3% (−0.6% vs SPY) | −3.5% (−4.0% vs SPY) | −7.4% (−8.2% vs SPY) |
| Aug 19, 2026 | Form 144 | Form 144: Shannon M. Parisotto plans to sell $600K | +3.8% (+3.6% vs SPY) | +6.4% (+6.6% vs SPY) | +0.9% (+1.5% vs SPY) |
| Aug 18, 2026 | Form 144 | Form 144: Nancy C Andrews plans to sell $163K | −2.6% (−1.9% vs SPY) | +4.1% (+5.3% vs SPY) | −4.7% (−2.3% vs SPY) |
| Aug 18, 2026 | Insider sale | Andrews Nancy C sold $163K | −2.6% (−1.9% vs SPY) | +4.1% (+5.3% vs SPY) | −4.7% (−2.3% vs SPY) |
| Aug 11, 2026 | Form 144 | Form 144: Birgit Girshick plans to sell $1.8M | +1.8% (+2.1% vs SPY) | +3.4% (+3.5% vs SPY) | +0.5% (+1.9% vs SPY) |
| Aug 11, 2026 | Form 144 | Form 144: Shannon M. Parisotto plans to sell $1.0M | +1.8% (+2.1% vs SPY) | +3.4% (+3.5% vs SPY) | +0.5% (+1.9% vs SPY) |
| Aug 10, 2026 | Form 144 | Form 144: James Foster plans to sell $7.9M | +3.5% (+3.5% vs SPY) | +4.6% (+4.2% vs SPY) | +4.8% (+5.8% vs SPY) |
| Aug 6, 2026 | Form 144 | Form 144: Michael Knell plans to sell $1.7M | +1.8% (+2.0% vs SPY) | +8.7% (+8.3% vs SPY) | +11.8% (+11.3% vs SPY) |
| Aug 6, 2026 | Form 144 | Form 144: Victoria Creamer plans to sell $1.1M | +1.8% (+2.0% vs SPY) | +8.7% (+8.3% vs SPY) | +11.8% (+11.3% vs SPY) |
| Aug 6, 2026 | Insider sale | Knell Michael Gunnar sold $1.7M | +1.8% (+2.0% vs SPY) | +8.7% (+8.3% vs SPY) | +11.8% (+11.3% vs SPY) |
| Aug 6, 2026 | Insider sale | Creamer Victoria L sold $1.1M | +1.8% (+2.0% vs SPY) | +8.7% (+8.3% vs SPY) | +11.8% (+11.3% vs SPY) |
| Aug 5, 2026 | Earnings | Earnings: beat the EPS estimate by 10.3% | +10.8% (+11.0% vs SPY) | +18.6% (+18.7% vs SPY) | +22.0% (+22.8% vs SPY) |
| Aug 5, 2026 | Form 144 | Form 144: Shannon M Parisotto plans to sell $1.3M | +10.8% (+11.0% vs SPY) | +18.6% (+18.7% vs SPY) | +22.0% (+22.8% vs SPY) |
| Jun 29, 2026 | Form 144 | Form 144: James C Foster plans to sell $16.9M | +4.5% (+2.8% vs SPY) | +7.0% (+4.0% vs SPY) | +10.8% (+9.2% vs SPY) |
| May 11, 2026 | 8-K | Directors and officers: departures, appointments, pay | +0.1% (+0.3% vs SPY) | −11.7% (−11.6% vs SPY) | +10.0% (+11.9% vs SPY) |
| May 7, 2026 | Earnings | Earnings: beat the EPS estimate by 5.4% | 0.0% (+0.3% vs SPY) | −11.0% (−12.1% vs SPY) | −0.2% (−0.7% vs SPY) |
| Feb 18, 2026 | 8-K | Directors and officers: departures, appointments, pay | +3.9% (+4.1% vs SPY) | +5.9% (+4.9% vs SPY) | −3.2% (+0.8% vs SPY) |
| Feb 18, 2026 | Earnings | Earnings: beat the EPS estimate by 1.9% | −0.3% (−0.8% vs SPY) | +4.6% (+4.0% vs SPY) | −0.9% (+2.3% vs SPY) |
| Jan 9, 2026 | 8-K | Directors and officers: departures, appointments, pay | −1.0% (−1.1% vs SPY) | −0.5% (−0.2% vs SPY) | −19.8% (−19.5% vs SPY) |
Insiders’ record here
In the year on the chart, Charles River Laboratories International's insiders reported 0 open-market buys ($0) and 3 sales ($3.0M).
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Charles River Laboratories International: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.